COMPLIANCE & TRANSPARENCY

Regulatory Information

Notices regarding HTL-RTT's investigational status and the scope of this website.

Important Notice

Retatrutide is an investigational compound and has not been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other regulatory authority for any indication.

1. Investigational Status of Retatrutide

Retatrutide (also known by the research designation LY3437943) is a synthetic peptide under active clinical investigation. As of the date of this publication, retatrutide has not received regulatory approval for marketing or clinical use in any jurisdiction. Retatrutide is the subject of registered clinical trials publicly accessible on ClinicalTrials.gov.

The investigational status of a compound means that its safety and efficacy have not been established to the satisfaction of any regulatory authority. No safety, efficacy, or suitability claims are made on this website regarding retatrutide or any product associated with it.

2. Scope and Purpose of This Website

This website is a scientific information and product-design showcase resource for HTL-RTT, presented by Health Therapies Lifestyle. Its purpose is to:

  • Describe the physical design characteristics of the HTL-RTT pen-format product concept;
  • Provide factual information about the investigational compound retatrutide and its receptor pharmacology;
  • Link to publicly available peer-reviewed scientific literature and registered clinical trial records;
  • Present verified batch identification and analytical records where independently confirmed.

This website does not:

  • Facilitate the purchase, sale, prescription, or dispensing of any pharmaceutical substance;
  • Provide dosing, injection, administration, or compounding instructions;
  • Make claims of safety, efficacy, or suitability for human or veterinary use;
  • Constitute medical, legal, or regulatory advice;
  • Represent that research-use or private-membership designations confer authorization to distribute an unapproved drug.

3. No Medical Advice

Nothing on this website constitutes medical advice, diagnosis, treatment recommendation, or clinical guidance. Visitors seeking medical information about metabolic conditions, obesity, diabetes, or related health topics should consult a licensed healthcare professional.

4. Applicable Regulatory Frameworks

The distribution, compounding, and administration of investigational compounds in the United States is governed by the Federal Food, Drug, and Cosmetic Act (FD&C Act), FDA regulations, and, where applicable, state pharmacy laws. Internationally, equivalent frameworks apply through regulatory bodies such as the EMA, MHRA, Health Canada, and TGA.

This website does not constitute a representation that any activity described herein is lawful under any applicable regulatory framework. Users are solely responsible for ensuring that their activities comply with all applicable laws and regulations.

5. No Endorsement or Affiliation

HTL-RTT and Health Therapies Lifestyle are not affiliated with Eli Lilly and Company, which holds the investigational new drug application for retatrutide (LY3437943). References to clinical trials and published research are for informational purposes only and do not imply endorsement by any research sponsor, institution, or regulatory body.

6. Updates to This Notice

Regulatory status of investigational compounds may change. Health Therapies Lifestyle will endeavour to update this page when material changes to the regulatory status of retatrutide are publicly known. However, this page does not constitute a real-time regulatory compliance resource, and users should consult applicable regulatory authorities for current information.

For regulatory enquiries, please use the Contact page.